RxDoctor Payments Data

Regina Zambrano

Clinical Genetics (M.D.) · New Orleans, LANPI 1659574739

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $88,024 of the $121,296 with a category attached, or 72.6%. AstraZeneca accounts for 80.6% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $43,535, more than ten times the $165 reported in 2019.

$121,296in general payments, 2019–2025

Across 192 payments — averaging $631.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$98K
  • Chiesi USA, Inc.$12K
  • Sanofi$10K
  • Novartis$320
  • Genentech USA, Inc.$140
  • Sanofi US Services Inc.$119
  • plus $280 from 8 others

What the payments were for

  • Consulting fees$13,51011%
  • Speaking & faculty fees$88,02473%
  • Travel & lodging$14,99512%
  • Food & beverage$4,7674%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical genetics (m.d.) providers in Louisianato place this figure against a meaningful peer group, so we don't.

Other clinical genetics (m.d.) in New Orleans

Where these figures come from

Is this you, or does something look wrong? →